Hospital General Universitario de Valencia -ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2022

  1. SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 724-732

2020

  1. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

    Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861

2018

  1. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537

2017

  1. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 682-694

2016

  1. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

    Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579

2015

  1. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma

    Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750

  2. Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 17, Núm. 10, pp. 763-771

2014

  1. Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]

    Journal of Neuro-Oncology

2012

  1. SEOM guideline for the treatment of malignant glioma

    Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 545-550

2010

  1. Extended-schedule dose-dense temozolomide in refractory gliomas

    Journal of Neuro-Oncology, Vol. 96, Núm. 3, pp. 417-422